TearClear, an ophthalmic pharmaceutical company that transforms trusted drugs into branded best-in-class therapies, announced today that the company’s lead product, TC-002 (latanoprost ophthalmic solution 0.005%) met the primary and all secondary endpoints in the CLEAR Phase 3 pivotal trial. With these results, TearClear plans to file a New Drug Application (NDA) with the US Food and Drug Administration (FDA) in the first quarter of 2023. Upon approval, TC-002 will offer patients the first and only means of delivering preservative-free doses of latanoprost from conventional multi-dose bottles.
Bailey’s executive experience in the Ophthalmology industry further strengthens the organization.
TearClear Raises $22 Million & Adds Stuart Raetzman to BOD to Advance Multiple Clinical Programs in Development
TearClear Raises $22 Million from Visionary Ventures, Bluestem Capital, Flying L Partners, and KKR to Advance Multiple Clinical Programs in Development. In addition to the financing, TearClear also announces the appointment of the former Chief Executive Officer of Galderma, Stuart Raetzman, to Board of Directors.
Robert J. Dempsey recently joined TearClear, an emerging global ophthalmic pharmaceutical company with a focus on eye drops that are preserved safely prior to administering dosing, as Chief Executive Officer. Prior to this role, Mr. Dempsey held positions at Shire (Takeda, now Novartis), Bausch + Lomb, Allergan and Inspire Pharmaceuticals. What follows is a Q&A with Mr. Dempsey, where he reveals, among other things, his love of American history.
In this week’s OIS Podcast, Dr. Ehsan Sadri speaks with Bob Dempsey who just assumed the CEO role for TearClear. Let’s hear how Bob’s experience taking Xiidra to market for Shire led him to the driver’s seat for one of the most promising new drug-delivery companies.
TearClear Completes Initial Close of $25MM Series B Financing led by Visionary Ventures, Bluestem Capital, and Flying L. Additionally, TearClear has appointed Robert Dempsey to the CEO role. Robert Dempsey and Bill Link were interviewed by Eyewire news about the latest financing and CEO appointment.
TearClear aims to be the premier specialty pharmaceutical company assuring reliable delivery of preservative-free ophthalmic drugs from preserved multi-dose solutions.
TearClear closes series A financing and introduces leadership team of accomplished ophthalmology veterans with the proceeds going to advance the development of the Company’s delivery system for preservative-free ophthalmic drugs.